A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM). (KEYNOTE 183)
A study for patient with Multiple Myeloma using study drug pomalidomide
Sponsor: Merck Sharp & Dohme Corp.
Enrolling: Male and Female Patients
IRB Number: AAAQ6704
U.S. Govt. ID: NCT02576977
Contact: Siyang Leng MD: 646-317-4840 / sl4076@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) with or without pomalidomide and low dose dexamethasone in subjects with refractory or relapsed and refractory Multiple Myeloma (rrMM) measured by the rates of response to treatment, disease progression (disease getting worse) and survival.
This study is closed
Investigator
Siyang Leng, MD
Do You Qualify?
Have you been diagnosed with multiple myeloma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Siyang Leng MD
sl4076@cumc.columbia.edu
646-317-4840
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE